Pfizer’s Eliquis Hits $14.4B in 2025, Targets 10-15% Growth in 2026
Pfizer’s co-developed Eliquis generated $14.4B in 2025, up 8% year over year, and is forecast to grow 10-15% in 2026 after a price reduction to boost patient access. Sales are expected to concentrate in H2 2026 before stepping down by $1.5-2.0B in 2027.
1. Eliquis 2025 Sales and Growth
Pfizer’s co-marketed blood thinner Eliquis generated $14.4 billion in 2025, representing an 8% year-over-year increase driven by sustained global demand.
2. 2026 Outlook and 2027 Dip Forecast
Management forecasts 10-15% sales growth for 2026 after implementing a price reduction to expand patient access, with sales weighted to the second half of the year and a 2027 decline of $1.5-2.0 billion anticipated.
3. Competitive Landscape and Pricing Strategy
Eliquis faces mounting competition from emerging generic anticoagulants, making access-expanding price cuts critical to sustaining market share and mitigating long-term pricing pressures.